Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Charles helps men regain control over their daily health concerns by starting with their personal health.
Germitec is a healthcare company focused on developing ultraviolet light disinfection systems aimed at improving hospital hygiene. The company specializes in high-level disinfection using UV-C technology, which is designed to effectively reprocess non-lumen medical devices. By simplifying safety protocols and reducing the time and responsibility of healthcare professionals, Germitec's systems help transform clinical practices and minimize the risk of cross-infection within medical facilities.
Damae Medical is a medtech company based in Paris, France, specializing in innovative imaging technology for the medical field. The company has developed a device that allows for in-vivo imaging of biological tissues at a cellular level. This technology enables dermatologists to assess the malignancy of tumors quickly and efficiently through simple contact with the skin's surface, eliminating the need for tissue excision and processing. By providing cellular-resolution imaging similar to traditional histology, Damae Medical aims to enhance skin cancer diagnosis and facilitate immediate, non-invasive assessments for healthcare professionals. The company's mission focuses on leveraging bio-photonics to create new opportunities in medical imaging and diagnostics.
Sunrise focuses on addressing the widespread issue of sleep disorders, particularly sleep apnea, which affects nearly one billion people globally. The company has developed a 3-gram sensor that provides a rapid, at-home diagnosis of sleep apnea, utilizing trigeminal drive analysis to detect respiratory events. This certified medical device connects seamlessly to a smartphone, allowing for easy use and immediate results. Clinical studies have demonstrated that Sunrise's technology matches the accuracy of traditional in-lab sleep studies but at a significantly lower cost. After testing, patients can consult with certified sleep doctors online or visit local sleep centers, streamlining the diagnostic process. With a large percentage of sleep apnea cases remaining undiagnosed, Sunrise offers a crucial solution for patients, caregivers, and insurers, enhancing the accessibility and efficiency of sleep disorder diagnostics.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.
Omnidoc is a tele-expertise platform focused on enhancing communication among healthcare professionals. It enables the exchange of medical opinions by facilitating phone-based medical verification for patients who qualify for health insurance. The platform serves medical institutions and private physicians by streamlining the process of obtaining informal medical opinions, strengthening connections between primary and specialized care providers, and centralizing requests from correspondents. Additionally, it allows users to identify and connect with doctors and healthcare organizations, thereby improving the quality and security of the opinions exchanged. Omnidoc also automates several administrative tasks, contributing to a more efficient healthcare experience for both providers and patients.
SmartCatch specializes in liquid biopsy technology aimed at enhancing cancer detection and treatment. The company has developed a minimally invasive method to extract circulating tumor cells, offering a series of products focused on the capture and isolation of these cells. This technology provides researchers and clinicians with valuable data that can significantly improve cancer patient outcomes. By empowering the medical community with advanced tools, SmartCatch contributes to the ongoing battle against cancer, facilitating better diagnostic and therapeutic approaches.
Arkhn is a company focused on healthcare data interoperability, addressing challenges related to accessing and managing healthcare data. It develops medical enterprise software that standardizes healthcare information to enhance patient care and support medical teams. By improving data accessibility, Arkhn aims to facilitate medical research and innovation while streamlining the operations of healthcare centers. This enables healthcare establishments to provide better support for patients and caregivers, ultimately accelerating advancements in the healthcare sector.
Medlumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company focuses on developing integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method providing detailed information about tissue structures. Medlumics' radiofrequency cardiac ablation system enhances the treatment process by delivering real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation aims to reduce recurrence rates and technical complexity in procedures, ultimately increasing safety for patients undergoing cardiac interventions.
DeepUll is a biotechnology company dedicated to developing an innovative diagnostic system for early-stage sepsis. The company's approach focuses on rapidly identifying pathogens and delivering antibiogram results within hours. By utilizing artificial intelligence, DeepUll is able to determine the infective agent and provide insights into antimicrobial susceptibility, which helps reduce unnecessary antibiotic use. This system not only enables quick detection of pathogens and antibiotic resistance without the need for prior cultivation but also allows healthcare providers to assess a patient's immunological and functional status. Consequently, DeepUll's technology empowers doctors to predict the onset and progression of sepsis, facilitating timely clinical interventions even before symptoms manifest.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.
Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.
Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.
FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.
PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.
Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.
PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.
Cardiologs is a medical technology company founded in 2014 that focuses on enhancing cardiac diagnostics through the use of medical-grade artificial intelligence and cloud technology. The company's flagship product, the Cardiologs Holter solution, leverages a proprietary database of over 18 million recordings, underpinned by numerous clinical publications that affirm its diagnostic accuracy. Cardiologs aims to democratize access to expert cardiac care worldwide by providing healthcare practitioners with advanced tools for electrocardiogram interpretation and automatic heart disorder screening, thereby streamlining the diagnostic process and improving patient outcomes. Their innovative approach combines cutting-edge deep learning technology with a commitment to making high-quality cardiac diagnostics accessible to all.
FeetMe is a digital health company specializing in advanced technology for gait and activity assessments in both clinical and real-world settings. The company develops innovative wearable products, particularly smart insoles equipped with pressure sensors and motion analysis algorithms. These products enable real-time monitoring of patients' mobility and posture, facilitating comprehensive evaluations of movement disorders and mobility constraints. By providing relevant digital biomarkers, FeetMe aims to support clinical research and enhance patient care, allowing healthcare professionals to track disease progression, improve functional outcomes, and optimize treatment strategies.
Sensome is a company that specializes in developing innovative remote monitoring technology aimed at transforming invasive vascular medical devices into connected healthcare solutions. Their patent-pending sensor technology utilizes impedance-based micro-sensors combined with machine learning algorithms to provide instantaneous and non-invasive identification of tissue composition in contact with medical devices. This breakthrough addresses the limitations of traditional vascular imaging techniques, enhancing both intervention procedures and patient follow-up. Currently, Sensome's team is focused on creating vascular access devices integrated with this proprietary sensor technology, with future plans to equip implantable devices for various medical applications, including neurovascular, peripheral vascular, and cardiovascular fields.
Damae Medical is a medtech company based in Paris, France, specializing in innovative imaging technology for the medical field. The company has developed a device that allows for in-vivo imaging of biological tissues at a cellular level. This technology enables dermatologists to assess the malignancy of tumors quickly and efficiently through simple contact with the skin's surface, eliminating the need for tissue excision and processing. By providing cellular-resolution imaging similar to traditional histology, Damae Medical aims to enhance skin cancer diagnosis and facilitate immediate, non-invasive assessments for healthcare professionals. The company's mission focuses on leveraging bio-photonics to create new opportunities in medical imaging and diagnostics.
Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.
Advanced Perfusion Diagnostics is a medical technology company based in Lyon, France, specializing in the development and manufacturing of innovative patient monitoring systems. The company is dedicated to providing clinicians with critical indicators of tissue perfusion, which are essential for assessing patient health. One of its key products, the IKORUS® monitoring system, addresses a significant gap in the market by enabling early detection of microcirculatory alterations. This advancement allows physicians to explore new investigative fields and improve existing therapeutic practices. The monitoring system is specifically designed to assess intestinal tissue perfusion, guiding novel circulatory therapies and enhancing resuscitation strategies, ultimately aiming to reduce patient complications and treatment costs.
BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through the development of digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling remote monitoring of continuous electrophysiological signals, BioSerenity aims to optimize patient care pathways in cardiology, neurology, and sleep disorders. The data collected from these devices, once anonymized, will be made available to researchers at the Institut du Cerveau et de la Moelle épinière, contributing to advancements in epilepsy research and improving diagnostic methods for the future.
PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.
PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.
STAT-Diagnostica specializes in the development of near-patient testing products aimed at enhancing healthcare delivery, particularly in critical care situations where rapid results are essential. The company's flagship product, DiagCORE, is a portable multi-analyte diagnostic device that integrates molecular and immunoassay testing capabilities. This innovative instrument allows healthcare providers to conduct a variety of tests within a single device, streamlining the diagnostic process across different clinical settings. By focusing on timely and efficient patient care, STAT-Diagnostica addresses the growing need for quick and accurate diagnostic solutions in the healthcare sector.
PathoQuest SAS is a biotechnology company that specializes in advanced metagenomics for pathogen detection, having originated as a spin-off from Institut Pasteur. The company utilizes proprietary next-generation sequencing (NGS) technology, which combines innovative sample preparation with a comprehensive database of pathogen genomic information. This approach allows clinicians and biopharmaceutical professionals to enhance the detection of infectious agents in various biological samples. PathoQuest's Viral Safety testing service, aimed at biopharmaceutical companies, represents its first commercial application and has rapidly generated revenue from major industry players. The company's cloud-based bioinformatics platform and automated analysis pipeline further facilitate improved pathogen detection, making its solutions valuable for both clinical and biopharmaceutical quality assurance.